Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $218.53 million.

GUIDANCE:

Corcept Therapeutics sees FY2025 revenue of $800-850 million, versus the consensus of $852.7 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.